Our very thin CLL Society team is busy preparing for the ASCO (American Society of Clinical Oncology) 2015 Annual meeting which starts at the end of this week in Chicago, but we still found time to bring three diverse and instructive new topics to our website https://cllsociety.org for this week.
Today, we posted Dr. Adrian Weistner’s thoughtful and well-considered interview from ASH (American Society of Hematology) 2014 on what is known and unknown about novel therapies. You can find that here.
Expect more video interviews and commentaries from ASH 2014 over the next several weeks.
On Wednesday, the camera is turned on yours truly for my personal take on CLL topics of interest. We include the short video and an updated transcript on this week’s topic of oral versus IV medications. I think you might be surprised at some of the issues and non-issues in what would seem at first glance to be should be a simple choice. This new section will roll out here.
This will be only the first in a long series of instructional postings on the various CLL therapies.
On Friday, we will post an up to the minute review of and link to an important ASCO 2105 abstract about the latest data on combining idelalisib with chemo-immunotherapy. You will find it here on Friday.
Please let us know what you think, especially about my reading and the transcripts of my monologues. You can contact us here.
We are constantly working to respond to the unmet needs of the CLL community, so we listen carefully to what you write us and try to respond as best we can.
We don’t have a big production budget and team or large institutional backing, but we keep going to offer up the most robust and recent, yet still accessible information with no gloss and no agenda other than to inform our community.
Because we believe that SMART PATIENTS GET SMART CARE™
We are all in this together.
Brian Koffman, MD
Volunteer Medical Director of the CLL Society